- €86.19bn
- €103.69bn
- €46.72bn
Brief: Sanofi Q2 Net Income EUR 343 Million
Brief: Sanofi Q2 Business EPS At €2.09 Beats Consensus
Sanofi raises sales outlook on Dupixent strength in boost for new CEO
Brief: Sanofi Announces Decision Not To Submit Amlitelimab In Atopic Dermatitis For Global Regulatory Reviews
Celldex to stop skin disease study after trial setback
Celldex to stop skin disease study after trial setback
Brief: Scribe Therapeutics - IPO Price Expected Between $13 And $15 Per Share - SEC Filing
Merck gets US FDA nod for first-in-its-class oral cholesterol drug (updated)
Merck's cholesterol pill gets US FDA approval
Sanofi sues Pfizer, Moderna over COVID shot technology
US FDA approves Sanofi's wearable injector form of blood cancer drug (updated)
Brief: Sanofi: Subcutaneous Sarclisa Escena Approved In US
US FDA approves Sanofi's wearable injector form of blood cancer drug
Brief: FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9
Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine (updated)
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
AstraZeneca secures ex-China license for Sino Biopharmaceutical's experimental COPD drug (updated)
HSBC says European healthcare can benefit if AI, tech weaken
Brief: Adocia Says Sanofi’S Exclusive Right For Partnership Agreement For Development Of M1Pram Has Expired